



Fondazione IRCCS
Policlinico San Matteo di Pavia



Gruppo Italiano
Oncologia
Nefrologica

3rd

Pavia International Symposium on **Advanced Kidney Cancer**

June 30th - July 1st 2011

Collegio Ghislieri - PAVIA



Fondazione IRCCS Policlinico San Matteo
Pavia

Presidente

CAMILLO PORTA

Fondazione IRCCS Policlinico San Matteo - Pavia

Co-Presidente

SERGIO BRACARDA

U.O.C. Oncologia Medica
Ospedale San Donato - USL 8, Arezzo

Segreteria Scientifica

CHIARA PAGLINO

ILARIA IMARISIO

Oncologia Medica
Fondazione IRCCS Policlinico San Matteo - Pavia

Segreteria Organizzativa

START PROMOTION srl

Via Mauro Macchi, 50 - 20124 Milano

Tel. 02-67071383 - Fax 02-67072294

E-mail: info@startpromotion.it

www.startpromotion.it

FACULTY

- | | | | |
|---------------|----------------------|--------------|---------------------|
| A. Bamias | (Athens - GR) | F. Massari | (Verona) |
| A. Bearz | (Aviano - Pordenone) | M. Milella | (Roma) |
| S. Bracarda | (Arezzo) | A. Mosca | (Novara) |
| M. Brunelli | (Verona) | C. Ortega | (Candiolo - Torino) |
| F. Calabrò | (Roma) | C. Paglino | (Pavia) |
| G. Cartenì | (Napoli) | C. Porta | (Pavia) |
| B. Escudier | (Villejuif - F) | G. Procopio | (Milano) |
| V. Ficarra | (Padova) | R. Sabbatini | (Modena) |
| G. Fornarini | (Genova) | R. Salvioni | (Milano) |
| E. Galligioni | (Trento) | D. Santini | (Roma) |
| D. Heng | (Aberta, Canada) | F. Stenner | (Zurich - CH) |
| I. Imarisio | (Pavia) | C. Sternberg | (Roma) |
| G. Martignoni | (Verona) | C. Szczylik | (Warsaw - PL) |
| G. Martorana | (Bologna) | G.P. Tortora | (Verona) |
| C. Masini | (Modena) | P. Zucali | (Milano) |



PROGRAM

June 30

1st session - Open issues I (Moderatori: S. Bracarda & C. Porta)

9,30-9,50

Could pathology help us to define better treatment strategies?

M. Brunelli, G. Martignoni

9,50-10,10

Escape mechanisms from molecularly targeted agents: from biological insights to newer treatment approaches

F. Massari, G.P. Tortora

10,10-10,30

Does modulation of the immune system still play a role in the era of molecularly targeted agents?

B. Escudier

10,30-10,45

DISCUSSION

10,45-11,00

COFFEE BREAK

2nd session - Special situations I (Moderatori: P. Zucali & R. Sabbatini)

11,00-11,20

Neo-adjuvant treatment: pro

R. Salvioni

11,20-11,40

Neo-adjuvant treatment: cons

C. Szczylik

11,40-12,00

Should we treat patients with severe kidney impairment or under dialytic replacement therapy?

R. Sabbatini



12,00-12,20

**Poor risk features and poor performance status:
the same treatment?**

G. Procopio

12,20-12,35

DISCUSSION

12,35-14,20

LUNCH

**3rd session - Do we know all we should know about
molecularly targeted agents?** (Moderatori: *G. Procopio & G. Fornarini*)

14,20-14,40

Bevacizumab with or without Interferon: lights and shadows

S. Bracarda

14,40-15,00

**Advanced RCC: is there a reasonable algorithm of
treatment?**

C. Porta

15,00-15,20

**Pazopanib: from a 'me too' TKI to a breakthrough option in
the management of mRCC**

F. Calabrò, C. Sternberg

15,20-15,40

Everolimus: from the post-TKIs setting to what?

A. Bamias

15,40-15,55

DISCUSSION


15,55-16,10

COFFEE BREAK

3rd Pavia International Symposium on Advanced Kidney Cancer

4th session - Special situations II (Moderatori: C. Porta & C. Masini)

- 16,10-16,30 **Which is the standard of treatment for non-clear cell mRCC, if any?**
C. Paglino
- 16,30-16,50 **Cardiopathic patients: to treat or not to treat ... and how?**
C. Ortega
- 16,50-17,10 **The treatment of patients with brain metastases**
A. Mosca
- 17,10-17,30 **The mRCC Consortium: working together for a better care**
D. Heng
- 17,30-17,45 DISCUSSION





July 1

5th session (Moderatori: C. Porta & I. Imarisio)

9,30-9,50 **The 'Pieter De Mulder Young Investigator award lecture'**

6th session - Open issues II (Moderatori: A. Mosca & C. Paglino)

9,50-10,10 **Prognostic factors from localized tumors to advanced ones.
What to take and where to go**

V. Ficarra

10,10-10,30 **A meta-analysis of studies of sequential Sunitinib and
Sorafenib: have we lessons to learn?**

F. Stenner

10,30-10,50 **Sorafenib: really a second option or a surprise box?**

E. Galligioni

10,50-11,05 DISCUSSION

11,05-11,20 COFFEE BREAK

7th session - Special situations III (Moderatori: G. Martorana & G. Procopio)

11,20-11,40 **Which is the ideal first line therapy for elderly patients?**

A. Bearz

11,40-12,00 **From the biology of bone metastases to newer treatments**

D. Santini

12,00-12,20 **Sunitinib: have we exploited it at its best?**

G. Carteni, M. Milella

12,20-12,35 DISCUSSION

12,35-13,35 FAREWELL LUNCH AND DEPARTURES

On the occasion of the Third Pavia International Symposium, a scientific contest will take place to select the best paper on whatever aspect of the research (either experimental or clinical) on kidney cancer, presented by a young researcher (age <40 years).

The winner will be awarded a cheque of € 2.000.

This prize is dedicated to the memory of the late **Professor Pieter De Mulder**, who died because of that tumour he had been fighting for years.

The Author of the best paper will be awarded the De Mulder prize and entitled to present his/her work as oral presentation during the Symposium.



ECM

Questo Congresso darà diritto a **9** crediti ECM per l'anno 2011.
Il corso è aperto per le professioni di Medico Chirurgo.

Per la certificazione ECM è assolutamente indispensabile compilare in ogni sua parte (in particolare nome e cognome, data e luogo di nascita, codice fiscale e indirizzo e-mail) il modulo dati ECM, la scheda di valutazione ed il questionario di apprendimento. Durante il convegno dovrete registrare la vostra presenza in aula ad inizio e fine lavori. Per conseguire i crediti sarà necessario garantire la propria presenza al 100% del tempo totale, compilare tutta la modulistica e riconsegnarla al termine del Congresso alla postazione ECM presso la segreteria.

SEGRETERIA ORGANIZZATIVA START PROMOTION S.r.l.

Provider ECM N. 622

Via Mauro Macchi, 50 - 20124 Milano

Tel. 02 67071383 - Fax 02 67072294

www.startpromotion.it - E-mail: info@startpromotion.it

Con il contributo non condizionato di



Bayer HealthCare
Bayer Schering Pharma



GlaxoSmithKline



NOVARTIS



Oncology

